Vabysmo 6 mg Solution for Injection
PDF Leaflet Revision Date: 22 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of neovascular (wet) age-related macular degeneration, diabetic macular oedema, and macular oedema secondary to retinal vein occlusion.
Dosage (summary)
6 mg (0.05 mL) intravitreal injection every 4 weeks for the first 4 doses; then individualized based on disease activity.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use only if benefits outweigh risks; unknown if excreted in breast milk.
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Hypersensitivity to faricimab
Common side effects
- Cataract
- Conjunctival hemorrhage
- Vitreous detachment
- Increased intraocular pressure
- Eye pain
Counselling Points
- Monitor for symptoms of endophthalmitis
- Report any vision changes immediately
- Avoid driving until vision is stable after injection
Serious warnings
- Risk of endophthalmitis
- Transient increases in intraocular pressure
- Potential for arterial thromboembolic events
Important Disclaimer
The Vabysmo 6 mg Solution for Injection professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
